Surveillance for HCC among patients with HCV cirrhosis has been demonstrated to be cost-effective using either semiannual AFP and annual US or triple-phase computed tomography (CT) compared to no surveillance, with the cost of surveillance being less than $50,000 per quality-adjusted life year [34–36]. Here, AFP is linked to hepatocellular carcinoma.